Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma-Reference-Cited by-同舟云学术

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

Published:2008-11-15 Issue:10 Volume:113 Page:2734-2741
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Wang Michael,Fayad Luis,Cabanillas Fernando,Hagemeister Fredrick,McLaughlin Peter,Rodriguez Maria A,Kwak Larry W.,Zhou Yuhong,Kantarjian Hagop,Romaguera Jorge

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference34 articles.

1. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis;Meusers;Hematol Oncol,1989

2. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20 year period;Norton;Ann Oncol,1995

3. Mantle cell lymphoma: a clinicopathologic study of 80 cases;Argatoff;Blood,1997

4. Efficacy of 4 different regimens in 64 mantle cell lymphoma cases. Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes;Teodorovic;J Clin Oncol,1995

5. Patterns of survival in mantle cell lymphomas;Zucca;Ann Oncol,1995

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma;Leukemia Research;2023-11

2. Recent advances on blinatumomab for acute lymphoblastic leukemia;Experimental Hematology & Oncology;2019-11-06

3. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management;American Journal of Hematology;2019-04-19

4. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia;Journal of Hematology & Oncology;2019-02-08

5. Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting;American Journal of Health-System Pharmacy;2018-05-01